Risk-based ultrasound screening for thyroid cancer in obese patients is cost-effective

Stephanie Cham, Kyle Zanocco, Cord Sturgeon, Michael W. Yeh, Avital Harari*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: A higher body mass index (BMI) is associated with more advanced stages of thyroid cancer. Screening obese patients for thyroid cancer has been proposed but has yet to be examined for cost-effectiveness. The objective of this study was to assess the cost-effectiveness of ultrasound (US) screening of obese patients for thyroid cancer. Methods: A decision-tree model compared cost savings for the following: (i) base case scenario of an obese patient with thyroid nodule found by palpation, (ii) universal US screening of all obese patients, and (iii) risk-based US screening in obese patients. Risk-based screening consisted of patients who had at least one of four major identified risk factors for thyroid cancer (family history of thyroid cancer, radiation exposure, Hashimoto's thyroiditis, and/or elevated thyrotropin). Patients with nodules underwent established treatment and management guidelines. The model accounted for recurrence, complications, and long-term treatment/follow-up for five years. Outcome probabilities were identified from a literature review. Costs were estimated using a third-party payer perspective. Sensitivity analyses were performed to examine the impact of risk factor prevalence and US cost on the model. Results: The resulted costs per patient were $210.73 in the base case scenario, $434.10 in the universal US screening arm, and $166.72 in the risk-based screening arm. Risk-based screening remained cost-effective until more than 14% of obese patients had risk factors and with a wide variation of US costs ($0-$1113). Conclusion: Risk-based US screening in selected obese patients with risk factors for thyroid cancer is cost-effective. Recommendations for screening this subgroup will result in cost savings and a likely decreased morbidity and mortality in this subpopulation with more aggressive disease.

Original languageEnglish (US)
Pages (from-to)975-986
Number of pages12
JournalThyroid
Volume24
Issue number6
DOIs
StatePublished - Jun 1 2014

Fingerprint

Thyroid Neoplasms
Costs and Cost Analysis
Cost Savings
Cost-Benefit Analysis
Health Insurance Reimbursement
Hashimoto Disease
Decision Trees
Thyroid Nodule
Palpation
Thyrotropin
Body Mass Index
Guidelines
Morbidity
Recurrence
Mortality
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Cham, Stephanie ; Zanocco, Kyle ; Sturgeon, Cord ; Yeh, Michael W. ; Harari, Avital. / Risk-based ultrasound screening for thyroid cancer in obese patients is cost-effective. In: Thyroid. 2014 ; Vol. 24, No. 6. pp. 975-986.
@article{f6c62cfb68aa43a0bdbbc2041e58338c,
title = "Risk-based ultrasound screening for thyroid cancer in obese patients is cost-effective",
abstract = "Background: A higher body mass index (BMI) is associated with more advanced stages of thyroid cancer. Screening obese patients for thyroid cancer has been proposed but has yet to be examined for cost-effectiveness. The objective of this study was to assess the cost-effectiveness of ultrasound (US) screening of obese patients for thyroid cancer. Methods: A decision-tree model compared cost savings for the following: (i) base case scenario of an obese patient with thyroid nodule found by palpation, (ii) universal US screening of all obese patients, and (iii) risk-based US screening in obese patients. Risk-based screening consisted of patients who had at least one of four major identified risk factors for thyroid cancer (family history of thyroid cancer, radiation exposure, Hashimoto's thyroiditis, and/or elevated thyrotropin). Patients with nodules underwent established treatment and management guidelines. The model accounted for recurrence, complications, and long-term treatment/follow-up for five years. Outcome probabilities were identified from a literature review. Costs were estimated using a third-party payer perspective. Sensitivity analyses were performed to examine the impact of risk factor prevalence and US cost on the model. Results: The resulted costs per patient were $210.73 in the base case scenario, $434.10 in the universal US screening arm, and $166.72 in the risk-based screening arm. Risk-based screening remained cost-effective until more than 14{\%} of obese patients had risk factors and with a wide variation of US costs ($0-$1113). Conclusion: Risk-based US screening in selected obese patients with risk factors for thyroid cancer is cost-effective. Recommendations for screening this subgroup will result in cost savings and a likely decreased morbidity and mortality in this subpopulation with more aggressive disease.",
author = "Stephanie Cham and Kyle Zanocco and Cord Sturgeon and Yeh, {Michael W.} and Avital Harari",
year = "2014",
month = "6",
day = "1",
doi = "10.1089/thy.2013.0470",
language = "English (US)",
volume = "24",
pages = "975--986",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

Risk-based ultrasound screening for thyroid cancer in obese patients is cost-effective. / Cham, Stephanie; Zanocco, Kyle; Sturgeon, Cord; Yeh, Michael W.; Harari, Avital.

In: Thyroid, Vol. 24, No. 6, 01.06.2014, p. 975-986.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk-based ultrasound screening for thyroid cancer in obese patients is cost-effective

AU - Cham, Stephanie

AU - Zanocco, Kyle

AU - Sturgeon, Cord

AU - Yeh, Michael W.

AU - Harari, Avital

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Background: A higher body mass index (BMI) is associated with more advanced stages of thyroid cancer. Screening obese patients for thyroid cancer has been proposed but has yet to be examined for cost-effectiveness. The objective of this study was to assess the cost-effectiveness of ultrasound (US) screening of obese patients for thyroid cancer. Methods: A decision-tree model compared cost savings for the following: (i) base case scenario of an obese patient with thyroid nodule found by palpation, (ii) universal US screening of all obese patients, and (iii) risk-based US screening in obese patients. Risk-based screening consisted of patients who had at least one of four major identified risk factors for thyroid cancer (family history of thyroid cancer, radiation exposure, Hashimoto's thyroiditis, and/or elevated thyrotropin). Patients with nodules underwent established treatment and management guidelines. The model accounted for recurrence, complications, and long-term treatment/follow-up for five years. Outcome probabilities were identified from a literature review. Costs were estimated using a third-party payer perspective. Sensitivity analyses were performed to examine the impact of risk factor prevalence and US cost on the model. Results: The resulted costs per patient were $210.73 in the base case scenario, $434.10 in the universal US screening arm, and $166.72 in the risk-based screening arm. Risk-based screening remained cost-effective until more than 14% of obese patients had risk factors and with a wide variation of US costs ($0-$1113). Conclusion: Risk-based US screening in selected obese patients with risk factors for thyroid cancer is cost-effective. Recommendations for screening this subgroup will result in cost savings and a likely decreased morbidity and mortality in this subpopulation with more aggressive disease.

AB - Background: A higher body mass index (BMI) is associated with more advanced stages of thyroid cancer. Screening obese patients for thyroid cancer has been proposed but has yet to be examined for cost-effectiveness. The objective of this study was to assess the cost-effectiveness of ultrasound (US) screening of obese patients for thyroid cancer. Methods: A decision-tree model compared cost savings for the following: (i) base case scenario of an obese patient with thyroid nodule found by palpation, (ii) universal US screening of all obese patients, and (iii) risk-based US screening in obese patients. Risk-based screening consisted of patients who had at least one of four major identified risk factors for thyroid cancer (family history of thyroid cancer, radiation exposure, Hashimoto's thyroiditis, and/or elevated thyrotropin). Patients with nodules underwent established treatment and management guidelines. The model accounted for recurrence, complications, and long-term treatment/follow-up for five years. Outcome probabilities were identified from a literature review. Costs were estimated using a third-party payer perspective. Sensitivity analyses were performed to examine the impact of risk factor prevalence and US cost on the model. Results: The resulted costs per patient were $210.73 in the base case scenario, $434.10 in the universal US screening arm, and $166.72 in the risk-based screening arm. Risk-based screening remained cost-effective until more than 14% of obese patients had risk factors and with a wide variation of US costs ($0-$1113). Conclusion: Risk-based US screening in selected obese patients with risk factors for thyroid cancer is cost-effective. Recommendations for screening this subgroup will result in cost savings and a likely decreased morbidity and mortality in this subpopulation with more aggressive disease.

UR - http://www.scopus.com/inward/record.url?scp=84902183650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902183650&partnerID=8YFLogxK

U2 - 10.1089/thy.2013.0470

DO - 10.1089/thy.2013.0470

M3 - Article

VL - 24

SP - 975

EP - 986

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 6

ER -